Ropes & Gray advised Pfizer in connection with their participation in CellCentric’s $220 million oversubscribed Series D funding round to advance inobrodib, a first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma. The completion of the round was announced on May 6.
CellCentric is a privately held biotechnology company advancing inobrodib. Inobrodib is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, with additional indications under consideration. CellCentric is supported by a robust IP portfolio and external validation through clinical collaborations and strategic partnerships. Founded in Cambridge, UK, the company operates as a transatlantic business with offices in Boston.
Ropes & Gray also advised Pfizer on its $25 million strategic investment in CellCentric in 2023.
The team was led by emerging companies & venture capital partner Brad Flint, counsel David Dowling, and associates Velyana Borisova and Iain Fox, and included tax partner David Saltzman and litigation & enforcement partner Lisa Kaltenbrunner.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.